BioSig Technologies Announces Participation in Bates College’s Purposeful Work Initiative
Santa Monica, CA, March 21, 2018 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (OTCQB: BSGM), a medical device company developing a proprietary biomedical signal processing platform designed to address an unmet technology need for the $4.6 billion electrophysiology (EP) marketplace, today announced that the Company will be extending its summer internship positions to Bates students in the summer of 2018.
Located in Lewiston, Maine, Bates is internationally recognized as a leading college of the liberal arts, attracting 2,000 students from across the U.S. and around the world. Since 1855, Bates has been dedicated to educating the whole person through creative and rigorous scholarship in a collaborative residential community. Committed to opportunity and excellence, Bates has always admitted students without regard to gender, race, religion, or national origin. Cultivating intellectual discovery and informed civic action, Bates prepares leaders sustained by a love of learning and zeal for responsible stewardship of the wider world.
The Purposeful Work initiative developed by Bates is designed to support students as they explore interests, deepen skills and build their networks. Introduced under the leadership of current President Clayton Spencer, the program has successfully engaged some of the world’s leading companies as its core employers. The objectives of the program align with BioSig’s mission to provide a highly immersive learning experience. All students interning with BioSig are compensated by the company for their contributions, including travel and housing expenses. This additional financial support for student-interns is the company’s way of ensuring that students gain important applied experiences over the summer, without the possibility of increasing their debt burden.
“The internship component of the Purposeful Work initiative is successful because of the strong support we receive from Core Employers like Ken Londoner and his team at BioSig,” states Allen Delong, Senior Associate Dean for Purposeful Work at Bates. “For the CEO to be as involved, as collaborative, and as generous with his time and financial resources as Ken has been, I can guarantee Bates students will have a phenomenal summer experience at BioSig.”
“We believe that it is our duty to give the students the best possible career start. We have created a unique program, which gives interns a 360-degree overview of the business and challenges their critical thinking needed to deliver high-impact work in an entrepreneurial environment. We were impressed with the consistent commitment to excellence that Bates demonstrates, and we are confident that our partnership will allow us to take both of our programs to the next level,” commented Kenneth L. Londoner, Chairman and CEO of BioSig Technologies, Inc.
About BioSig Technologies
BioSig Technologies is a medical device company developing a proprietary biomedical signal processing technology designed to improve the $4.6 billion electrophysiology (EP) marketplace (www.biosigtech.com). Led by a proven management team and a veteran, independent Board of Directors, Los Angeles-based BioSig Technologies is preparing to commercialize its PURE EP(TM) System. The technology has been developed to address an unmet need in a large and growing market.
The Company’s first product, PURE EP System, is a novel cardiac signal acquisition and display system which is engineered to assist electrophysiologists in clinical decision making during procedures to diagnose and treat patients with abnormal heart rates and rhythms. BioSig’s main goal is to deliver technology to improve upon catheter ablation treatments for the prevalent and deadly arrhythmias, Atrial Fibrillation and Ventricular Tachycardia. BioSig has partnered with Minnetronix on technology development and is working toward FDA 510(k) clearance for the PURE EP System.
This press release contains “forward-looking statements.” Such statements may be preceded by the words “intends,” “may,” “will,” “plans,” “expects,” “anticipates,” “projects,” “predicts,” “estimates,” “aims,” “believes,” “hopes,” “potential” or similar words. Forward-looking statements are not guarantees of future performance, are based on certain assumptions and are subject to various known and unknown risks and uncertainties, many of which are beyond the Company’s control, and cannot be predicted or quantified and consequently, actual results may differ materially from those expressed or implied by such forward-looking statements. Such risks and uncertainties include, without limitation, risks and uncertainties associated with (i) our inability to manufacture our product candidates on a commercial scale on our own, or in collaboration with third parties; (ii) difficulties in obtaining financing on commercially reasonable terms; (iii) changes in the size and nature of our competition; (iv) loss of one or more key executives or scientists; and (v) difficulties in securing regulatory approval to market our product candidates. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company’s filings with the Securities and Exchange Commission (SEC), including the Company’s Annual Report on Form 10-K and its Quarterly Reports on Form 10-Q. Investors and security holders are urged to read these documents free of charge on the SEC’s website at http://www.sec.gov. The Company assumes no obligation to publicly update or revise its forward-looking statements as a result of new information, future events or otherwise.
Contact: Natasha Russkina BioSig Technologies, Inc. VP Business Development & Corporate Finance email@example.com +41 (0) 76 823 7527
Released March 21, 2018